Cited by 391PARP inhibition in cancer therapyDNA Repair MechanismsBRCA gene mutations in cancer

The DOI matches its Crossref record; 551 of the 559 references it cites were found in a registry or an index.

Therapeutic applications of PARP inhibitors: Anticancer therapy and beyond

Open access

Curtin, Nicola J., Szabo, Csaba·2013·Molecular Aspects of Medicine

DOI 10.1016/j.mam.2013.01.006PMC PMC3657315

Open this paper in CoChat — free account

Abstract

The aim of this article is to describe the current and potential clinical translation of pharmacological inhibitors of poly(ADP-ribose) polymerase (PARP) for the therapy of various diseases. The first section of the present review summarizes the available preclinical and clinical data with PARP inhibitors in various forms of cancer. In this context, the role of PARP in single-strand DNA break repair is relevant, leading to replication-associated lesions that cannot be repaired if homologous recombination repair (HRR) is defective, and the synthetic lethality of PARP inhibitors in HRR-defective cancer. HRR defects are classically associated with BRCA1 and 2 mutations associated with familial breast and ovarian cancer, but there may be many other causes of HRR defects. Thus, PARP inhibitors may be the drugs of choice for BRCA mutant breast and ovarian cancers, and extend beyond these tumors if appropriate biomarkers can be developed to identify HRR defects. Multiple lines of preclinical data demonstrate that PARP inhibition increases cytotoxicity and tumor growth delay in combination with temozolomide, topoisomerase inhibitors and ionizing radiation. Both single agent and combination clinical trials are underway. The final part of the first section of the present review summarizes the current status of the various PARP inhibitors that are in various stages of clinical development. The second section of the present review summarizes the role of PARP in selected non-oncologic indications. In a number of severe, acute diseases (such as stroke, neurotrauma, circulatory shock and acute myocardial infarction) the clinical translatability of PARP inhibition is supported by multiple lines of preclinical data, as well as observational data demonstrating PARP activation in human tissue samples. In these disease indications, PARP overactivation due to oxidative and nitrative stress drives cell necrosis and pro-inflammatory gene expression, which contributes to disease pathology. Accordingly, multiple lines of preclinical data indicate the efficacy of PARP inhibitors to preserve viable tissue and to down-regulate inflammatory responses. As the clinical trials with PARP inhibitors in various forms of cancer progress, it is hoped that a second line of clinical investigations, aimed at testing of PARP inhibitors for various non-oncologic indications, will be initiated, as well.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.mam.2013.01.006

Cites

551 of 551 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

1 retracted

RETRACTED: Protective effects of 3-aminobenzamide, an inhibitor of poly (ADP-ribose) synthase in a carrageenan-induced model of local inflammation
Cuzzocrea, S., Zingarelli, B., Gilad, E., Hake, P. W., Salzman, A. L., & Szabó, C. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)01417-9 · Cited by 85
Retracted
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Nitric Oxide and Peroxynitrite in Health and Disease
Pacher, P., Beckman, J. S., & Liaudet, L. (2007) · Physiological Reviews · doi:10.1152/physrev.00029.2006 · Cited by 6,390
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Self-citation
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Murai, J., Huang, S.-Y. N., Das, B. B., Renaud, A., Zhang, Y., Doroshow, J. H., Ji, J. J., Takeda, S., & Pommier, Y. G. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2753 · Cited by 2,276
Heart-Lung Transplantation
Yarbrough, W. M., Robbins, R. C., & Mallidi, H. R. (2016) · CRC Press eBooks · doi:10.3109/9781439802571-25 · Cited by 2,161
Peroxynitrite: biochemistry, pathophysiology and development of therapeutics
Szabó, C., Ischiropoulos, H., & Radi, R. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2222 · Cited by 2,134
Self-citation
Hydrogen sulphide and its therapeutic potential
Szabó, C. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2425 · Cited by 2,039
Poly(ADP-ribose): novel functions for an old molecule
Schreiber, V., Dantzer, F., Amé, J., & de MURCIA, G. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1963 · Cited by 1,975
Physiological Implications of Hydrogen Sulfide: A Whiff Exploration That Blossomed
Wang, R. (2012) · Physiological Reviews · doi:10.1152/physrev.00017.2011 · Cited by 1,962
Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma
Herman, J. G., Umar, A., Polyák, K., Graff, J. R., Ahuja, N., Issa, J. J., Markowitz, S. D., Willson, J. K. V., Hamilton, S. R., Kinzler, K. W., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.12.6870 · Cited by 1,887
Mediation of Poly(ADP-Ribose) Polymerase-1-Dependent Cell Death by Apoptosis-Inducing Factor
Yu, S.-W., Wang, H., Poitras, M. F., Coombs, C., Bowers, W. J., Federoff, H. J., Poirier, G. G., Dawson, T. M., & Dawson, V. L. (2002) · Science · doi:10.1126/science.1072221 · Cited by 1,826
Hallmarks of 'BRCAness' in sporadic cancers
Turner, N. C., Tutt, A. N. J., & Ashworth, A. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1457 · Cited by 1,690
53BP1 Inhibits Homologous Recombination in Brca1-Deficient Cells by Blocking Resection of DNA Breaks
Bunting, S. F., Callén, E., Wong, N., Chen, H.-T., Polato, F., Gunn, A., Bothmer, A., Feldhahn, N., Fernandez-Capetillo, O., Cao, L., et al. (2010) · Cell · doi:10.1016/j.cell.2010.03.012 · Cited by 1,671
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
Tutt, A., Robson, M., Garber, J. E., Domchek, S. M., Audeh, M. W., Weitzel, J. N., Friedlander, M., Arun, B., Loman, N., Schmutzler, R. K., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60892-6 · Cited by 1,655
MISMATCH REPAIR IN REPLICATION FIDELITY, GENETIC RECOMBINATION, AND CANCER BIOLOGY
Modrich, P. L., & Lahue, R. S. (1996) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.65.070196.000533 · Cited by 1,510
The Therapeutic Potential of Poly(ADP-Ribose) Polymerase Inhibitors
Virág, L., & Szabó, C. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.3.375 · Cited by 1,373
Deficiency in the Repair of DNA Damage by Homologous Recombination and Sensitivity to Poly(ADP-Ribose) Polymerase Inhibition
McCabe, N., Turner, N. C., Lord, C. J., Kluzek, K., Białkowska, A., Swift, S., Giavara, S., O’Connor, M. J., Tutt, A. N. J., Zdzienicka, M. Z., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0140 · Cited by 1,311
Role of poly(ADP-ribose) formation in DNA repair
Satoh, M. S., & Lindahl, T. L. (1992) · Nature · doi:10.1038/356356a0 · Cited by 1,196
Blockade of Microglial Activation Is Neuroprotective in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Mouse Model of Parkinson Disease
Wu, D. C., Jackson-Lewis, V., Vila, M., Tieu, K., Teismann, P., Vadseth, C., Choi, D.-K., Ischiropoulos, H., & Przedborski, S. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-05-01763.2002 · Cited by 1,183
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
Gelmon, K. A., Tischkowitz, M. D., MacKay, H. J., Swenerton, K. D., Robidoux, A., Tonkin, K. S., Hirte, H. W., Huntsman, D. D., Clemons, M. J., Gilks, C. B., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70214-5 · Cited by 1,130
(ADP-ribose)n participates in DNA excision repair
Durkacz, B. W., Omidiji, O., Gray, D. A., & Shall, S. (1980) · Nature · doi:10.1038/283593a0 · Cited by 1,123
Nitric Oxide Activation of Poly(ADP-Ribose) Synthetase in Neurotoxicity
Zhang, J., Dawson, V. L., Dawson, T. M., & Snyder, S. H. (1994) · Science · doi:10.1126/science.8080500 · Cited by 1,118
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers
Sakai, W., Swisher, E. M., Karlan, B. Y., Agarwal, M. K., Higgins, J., Friedman, C., Villegas, E., Jacquemont, C., Farrugia, D. J., Couch, F. J., et al. (2008) · Nature · doi:10.1038/nature06633 · Cited by 1,086
Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells
Murcia, J. M., Niedergang, C., Trucco, C., Ricoul, M., Dutrillaux, B., Mark, M. P., Oliver, F. J., Masson, M., Dierich, A., LeMeur, M., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.14.7303 · Cited by 1,058
Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval
Fong, P. C. C., Yap, T. A., Boss, D. S., Carden, C. P., Mergui‐Roelvink, M., Gourley, C., Grève, J. D., Lubiński, J., Shanley, S., Messiou, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.9589 · Cited by 1,022
Poly(ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischemia
Eliasson, M. J. L., Sampei, K., Mandir, A. S., Hurn, P. D., Traystman, R. J., Bao, J., Pieper, A. A., Wang, Z., Dawson, T. M., Snyder, S. H., et al. (1997) · Nature Medicine · doi:10.1038/nm1097-1089 · Cited by 1,019
Resistance to therapy caused by intragenic deletion in BRCA2
Edwards, S. L., Brough, R., Lord, C. J., Natrajan, R., Vatcheva, R., Levine, D. A., Boyd, J., Reis-Filho, J. S., & Ashworth, A. (2008) · Nature · doi:10.1038/nature06548 · Cited by 1,011
Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia
Yrjänheikki, J., Keinänen, R., Pellikka, M., Hökfelt, T., & Koistinaho, J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15769 · Cited by 1,006
53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers
Bouwman, P., Aly, A., Escandell, J. M., Pieterse, M., Bartkova, J., van der Gulden, H., Hiddingh, S., Thanasoula, M., Kulkarni, A., Yang, Q., et al. (2010) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1831 · Cited by 1,001
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
Rottenberg, S., Jaspers, J. E., Kersbergen, A. J., van der Burg, E., Nygren, A. O. H., Zander, S. A. L., Derksen, P. W. B., de Bruin, M., Zevenhoven, J., Lau, A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806092105 · Cited by 975
Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors
Jagtap, P. G., & Szabó, C. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1718 · Cited by 915
Poly(ADP-ribose) polymerase is a mediator of necrotic cell death by ATP depletion
Ha, H. C., & Snyder, S. H. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.24.13978 · Cited by 913
Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells
Du, X., Matsumura, T., Edelstein, D., Rossetti, L., Zsengellér, Z. K., Szabó, C., & Brownlee, M. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18127 · Cited by 843
ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models
Donawho, C. K., Luo, Y., Luo, Y., Penning, T. D., Bauch, J. L., Bouska, J. J., Bontcheva-Diaz, V., Cox, B. F., DeWeese, T. L., Dillehay, L. E., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3039 · Cited by 784
On PAR with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1Preprint
Luo, X., & Kraus, W. L. (2012) · Genes & Development · doi:10.1101/gad.183509.111 · Cited by 759
Nuclear ADP-Ribosylation Reactions in Mammalian Cells: Where Are We Today and Where Are We Going?
Hassa, P. O., Haenni, S. S., Elser, M., & Hottiger, M. O. (2006) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00040-05 · Cited by 719
A requirement for PARP-1 for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage
El‐Khamisy, S. F. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg761 · Cited by 689
Role of poly(ADP-ribose) synthetase in inflammation and ischaemia–reperfusion
Szabó, C., & Dawson, V. L. (1998) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(98)01193-6 · Cited by 685
Nicotinamide mononucleotide activation of a new DNA-dependent polyadenylic acid synthesizing nuclear enzyme
Chambon, P., Weill, J. D., & Mandel, P. (1963) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(63)90024-x · Cited by 654
Poly(ADP-ribose) (PAR) polymer is a death signal
Andrabi, S. A., Kim, N. S., Yu, S.-W., Wang, H., Koh, D. W., Sasaki, M., Klaus, J. A., Otsuka, T., Zhang, Z., Koehler, R. C., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606526103 · Cited by 644
Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors
Mendes‐Pereira, A. M., Martin, S. A., Brough, R., McCarthy, A., Taylor, J. R., Kim, J., Waldman, T. A., Lord, C. J., & Ashworth, A. (2009) · EMBO Molecular Medicine · doi:10.1002/emmm.200900041 · Cited by 642
Functional interaction between PARP‐1 and PARP‐2 in chromosome stability and embryonic development in mouse
Murcia, J. M., Ricoul, M., Tartier, L., Niedergang, C., Huber, A., Dantzer, F., Schreiber, V., Amé, J., Dierich, A., LeMeur, M., et al. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg206 · Cited by 629
Ischemic Brain Injury is Mediated by the Activation of Poly(ADP-Ribose)Polymerase
Endres, M., Wang, Z., Namura, S., Waeber, C., & Moskowitz, M. A. (1997) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-199711000-00002 · Cited by 622
DNA strand breakage, activation of poly (ADP-ribose) synthetase, and cellular energy depletion are involved in the cytotoxicity of macrophages and smooth muscle cells exposed to peroxynitrite.
Szabó, C., Zingarelli, B., O’Connor, M. P., & Salzman, A. L. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.5.1753 · Cited by 622
PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
Ibrahim, Y. H., García-García, C., Serra, V., He, L., Torres‐Lockhart, K., Prat, A., Antón, P., Cozar, P., Guzmán, M., Grueso, J., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0348 · Cited by 616
4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: A Novel Bioavailable Inhibitor of Poly(ADP-ribose) Polymerase-1
Menear, K. A., Adcock, C., Boulter, R., Cockcroft, X. F., Copsey, L., Cranston, A. N., Dillon, K. J., Drzewiecki, J., Garman, S., Gomez, S., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8001263 · Cited by 608
Gender Differences in Human Sepsis
Schröder, J. (1998) · Archives of Surgery · doi:10.1001/archsurg.133.11.1200 · Cited by 608
Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation
Soriano, F. G., Virág, L., Jagtap, P. G., Szabó, É., Mabley, J. G., Liaudet, L., Marton, A., Hoyt, D. G., Murthy, K. G. K., Salzman, A. L., et al. (2001) · Nature Medicine · doi:10.1038/83241 · Cited by 602
Resistance to endotoxic shock as a consequence of defective NF‐κB activation in poly (ADP‐ribose) polymerase‐1 deficient mice
Oliver, F. J., Murcia, J. M., Nacci, C., Decker, P., Andriantsitohaina, R., Muller, S., de la Rubia, G., Stoclet, J., & de MURCIA, G. (1999) · The EMBO Journal · doi:10.1093/emboj/18.16.4446 · Cited by 583
Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells
Patel, A. G., Sarkaria, J. N., & Kaufmann, S. H. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1013715108 · Cited by 568
Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1 -Mutated Mouse Mammary Tumors
Jaspers, J. E., Kersbergen, A. J., Boon, U., Sol, W., van Deemter, L., Zander, S. A. L., Drost, R., Wientjens, E., Ji, J. J., Aly, A., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0049 · Cited by 532
Novel inhibitors of poly(ADP-ribose) synthetase
Purnell, M. R., & WHISH, W. J. D. (1980) · Biochemical Journal · doi:10.1042/bj1850775 · Cited by 529
Evidence of apoptotic cell death after experimental traumatic brain injury in the rat.
Rink, A. D., Fung, K., Trojanowski, J. Q., Lee, V. M.-Y., Neugebauer, E. A. M., & McIntosh, T. K. (1995) · Europe PMC (PubMed Central) · Cited by 521
Poly (ADP-ribose) polymerase, nitric oxide and cell death
Pieper, A. A. (1999) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(99)01292-4 · Cited by 512
Anticancer Chemosensitization and Radiosensitization by the Novel Poly(ADP-ribose) Polymerase-1 Inhibitor AG14361
Calabrese, C. R., Almassy, R., Barton, S., Batey, M. A., Calvert, A. H., Canan-Koch, S., Durkacz, B. W., Hostomsky, Z., Kumpf, R. A., Kyle, S., et al. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh005 · Cited by 487
Self-citation
Gene Expression Profile of BRCAness That Correlates With Responsiveness to Chemotherapy and With Outcome in Patients With Epithelial Ovarian Cancer
Konstantinopoulos, P. A., Spentzos, D., Karlan, B. Y., Taniguchi, T., Fountzilas, E., Francoeur, N. J., Levine, D. A., & Cannistra, S. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.5719 · Cited by 486
Specific inhibitors of poly(ADP-ribose) synthetase and mono(ADP-ribosyl)transferase.
Banasik, M., Komura, H., Shimoyama, M., & Ueda, K. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)45983-2 · Cited by 478
Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With BRCA1 or BRCA2 Mutations and Recurrent Ovarian Cancer
Kaye, S. B., Lubiński, J., Matulonis, U. A., Ang, J. E., Gourley, C., Karlan, B. Y., Amit, A., Bell‐McGuinn, K. M., Chen, L.-M., Friedlander, M. L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.9215 · Cited by 478
Lipoic acid – biological activity and therapeutic potential
Gorąca, A., Huk-Kolega, H., Piechota-Polańczyk, A., Kleniewska, P., Ciejka, E., & Skibska, B. (2011) · Pharmacological Reports · doi:10.1016/s1734-1140(11)70600-4 · Cited by 471
Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer
Juvekar, A., Burga, L. N., Hu, H., Lunsford, E. P., Ibrahim, Y. H., Balmañà, J., Rajendran, A., Papa, A., Spencer, K., Lyssiotis, C. A., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0336 · Cited by 468
Secondary BRCA1 Mutations in BRCA1 -Mutated Ovarian Carcinomas with Platinum Resistance
Swisher, E. M., Sakai, W., Karlan, B. Y., Wurz, K., Urban, N. D., & Taniguchi, T. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0088 · Cited by 459
Parthanatos, a messenger of death
David, K. K. (2009) · Frontiers in Bioscience · doi:10.2741/3297 · Cited by 450 · cited 3×
“…1998; Pieper et al., 1999; Mandir et al., 2000; Ying et al., 2002; Du et al., 2003a; Ying et al., 2005; Hamby et al., 2007; Duan et al., 2007; David et al., 2009) and inhibition of pro-inflammatory mediator production (Ullrich et al., 2001; Koh et al., 2004; Hassa et al., 2006; Kraus, 2008;…”
Background
Elevated Levels of Oxidative DNA Damage and DNA Repair Enzymes in Human Atherosclerotic Plaques
Martinet, W., Knaapen, M., Meyer, G. R. Y. D., Herman, A. G., & Kockx, M. M. (2002) · Circulation · doi:10.1161/01.cir.0000026393.47805.21 · Cited by 448
NMR and Molecular Modeling Investigation of the Mechanism of Activation of the Antitumor Drug Temozolomide and Its Interaction with DNA
Denny, B. J., Wheelhouse, R. T., Stevens, M. F. G., Tsang, L. L. H., & Slack, J. A. (1994) · Biochemistry · doi:10.1021/bi00197a003 · Cited by 442
Transcriptional control by PARP-1: chromatin modulation, enhancer-binding, coregulation, and insulation
Kraus, W. L. (2008) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2008.03.006 · Cited by 409
Poly(ADP-ribose) Polymerase-1-dependent Cardiac Myocyte Cell Death during Heart Failure Is Mediated by NAD+ Depletion and Reduced Sir2α Deacetylase Activity
Pillai, J. B., Isbatan, A., Imai, S., & Gupta, M. P. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m506162200 · Cited by 404
Estrogen as a Neuroprotectant in Stroke
Hurn, P. D., & Macrae, I. M. (2000) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-200004000-00001 · Cited by 401
Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors
Plummer, R., Jones, C., Middleton, M. R., Wilson, R. H., Evans, J., Olsen, A. L., Curtin, N. J., Boddy, A. V., McHugh, P. J., Newell, D. R., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1223 · Cited by 389
Self-citation
Poly(ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism
Mandir, A. S., Przedborski, S., Jackson-Lewis, V., Wang, Z.-Q., Simbulan-Rosenthal, C. M., Smulson, M. E., Hoffman, B. E., Guastella, D. B., Dawson, V. L., & Dawson, T. M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.10.5774 · Cited by 382
Evolution of Poly(ADP-ribose) Polymerase-1 (PARP-1) Inhibitors. From Concept to Clinic
Ferraris, D. V. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100012m · Cited by 380
Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death in vivo and in vitro
Mukhopadhyay, P., Rajesh, M., Bátkai, S., Kashiwaya, Y., Haskó, G., Liaudet, L., Szabó, C., & Pacher, P. (2009) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00795.2008 · Cited by 377
Role of the Peroxynitrite-Poly(ADP-Ribose) Polymerase Pathway in Human Disease
Pacher, P., & Szabó, C. (2008) · American Journal Of Pathology · doi:10.2353/ajpath.2008.080019 · Cited by 365
Innate Gender-based Proclivity in Response to Cytotoxicity and Programmed Cell Death Pathway
Du, L., Bayır, H., Lai, Y., Zhang, X., Kochanek, P. M., Watkins, S. C., Graham, S. H., & Clark, R. S. B. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m405461200 · Cited by 355
Endothelial dysfunction in a rat model of endotoxic shock. Importance of the activation of poly (ADP-ribose) synthetase by peroxynitrite.
Szabó, C., Cuzzocrea, S., Zingarelli, B., O’Connor, M. P., & Salzman, A. L. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119585 · Cited by 354
Apoptosis-Inducing Factor Triggered by Poly(ADP-Ribose) Polymerase and Bid Mediates Neuronal Cell Death after Oxygen-Glucose Deprivation and Focal Cerebral Ischemia
Culmsee, C., Zhu, C., Landshamer, S., Becattini, B., Wagner, E., Pellecchia, M., Blomgren, K., & Plesnila, N. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.2818-05.2005 · Cited by 339
Spontaneous Homologous Recombination Is Induced by Collapsed Replication Forks That Are Caused by Endogenous DNA Single-Strand Breaks
Saleh-Gohari, N., Bryant, H. E., Schultz, N., Parker, K. M., Cassel, T. N., & Helleday, T. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.16.7158-7169.2005 · Cited by 339
Genetic Disruption of Poly (ADP-Ribose) Synthetase Inhibits the Expression of P-Selectin and Intercellular Adhesion Molecule-1 in Myocardial Ischemia/Reperfusion Injury
Zingarelli, B., Salzman, A. L., & Szabó, C. (1998) · Circulation Research · doi:10.1161/01.res.83.1.85 · Cited by 337
A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer
Graeser, M., McCarthy, A., Lord, C. J., Savage, K., Hills, M., Salter, J., Orr, N., Parton, M., Smith, I. E., Reis-Filho, J. S., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1027 · Cited by 336
Radiosensitization and DNA repair inhibition by the combined use of novel inhibitors of DNA-dependent protein kinase and poly(ADP-ribose) polymerase-1
Veuger, S. J., Curtin, N. J., Richardson, C. J., Smith, G. C. M., & Durkacz, B. W. (2003) · PubMed · doi:10.25405/ncl.34607331 · Cited by 327
Self-citation
Selective Inhibition of BRCA2-Deficient Mammary Tumor Cell Growth by AZD2281 and Cisplatin
Evers, B., Drost, R., Schut, E., de Bruin, M., van der Burg, E., Derksen, P. W. B., Holstege, H. H., Liu, X., van Drunen, E., Beverloo, H. B., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4953 · Cited by 327
Ischemic Nitric Oxide and Poly (ADP-Ribose) Polymerase-1 in Cerebral Ischemia: Male Toxicity, Female Protection
McCullough, L. D., Zeng, Z., Blizzard, K. K., Debchoudhury, I., & Hurn, P. D. (2005) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600059 · Cited by 325
The effects of therapeutic sulfide on myocardial apoptosis in response to ischemia–reperfusion injury☆☆☆
Sodha, N. R., Clements, R., Feng, J., Liu, Y., Bianchi, C. F., Horvath, E. M., Szabó, C., & Sellke, F. W. (2008) · European Journal of Cardio-Thoracic Surgery · doi:10.1016/j.ejcts.2008.01.047 · Cited by 322
Peroxynitrite-mediated DNA strand breakage activates poly-adenosine diphosphate ribosyl synthetase and causes cellular energy depletion in macrophages stimulated with bacterial lipopolysaccharide
Zingarelli, B., O’Connor, M., Wong, H. R., Salzman, A. L., & Szabó, C. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.156.1.350 · Cited by 319
Role of Poly(ADP‐ribose) polymerase 1 (PARP‐1) in Cardiovascular Diseases: The Therapeutic Potential of PARP Inhibitors
Pacher, P., & Szabó, C. (2007) · Cardiovascular Drug Reviews · doi:10.1111/j.1527-3466.2007.00018.x · Cited by 317
Alterations in nitric oxide production in various forms of circulatory shock.
Szabó, C. (1995) · PubMed · Cited by 314
Intra-mitochondrial Poly(ADP-ribosylation) Contributes to NAD+ Depletion and Cell Death Induced by Oxidative Stress
Du, L., Zhang, X., Han, Y. Y., Burke, N. A., Kochanek, P. M., Watkins, S. C., Graham, S. H., Carcillo, J. A., Szabó, C., & Clark, R. S. B. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m301295200 · Cited by 310
Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial
Thomas, H. D., Calabrese, C. R., Batey, M. A., Canan, S. S., Hostomský, Z., Kyle, S., Maegley, K. A., Newell, D. R., Skalitzky, D. J., Wang, L.-Z., et al. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0552 · Cited by 309
Self-citation
Inhibition of the activity of poly(ADP ribose) synthetase reduces ischemia–reperfusion injury in the heart and skeletal muscle
Thiemermann, C., Bowes, J., Myint, F., & Vane, J. R. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.2.679 · Cited by 305
Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition
Johnson, N., Li, Y., Walton, Z. E., Cheng, K. A., Li, D., Rodig, S. J., Moreau, L. A., Unitt, C., Bronson, R. T., Thomas, H. D., et al. (2011) · Nature Medicine · doi:10.1038/nm.2377 · Cited by 293
Self-citation
DNA Repair Pathways in Clinical Practice: Lessons From Pediatric Cancer Susceptibility Syndromes
Kennedy, R. D., & D’Andrea, A. D. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.4171 · Cited by 290
Hydrogen sulfide replacement therapy protects the vascular endothelium in hyperglycemia by preserving mitochondrial function
Suzuki, K., Oláh, G., Módis, K., Coletta, C., Kulp, G., Gerő, D., Szoleczky, P., Chang, T., Zhou, Z., Wu, L., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1105121108 · Cited by 287
Inhibition of poly (ADP-ribose) Synthetase Attenuates Neutrophil Recruitment and Exerts Antiinflammatory Effects
Szabó, C., Lim, L. H. K., Cuzzocrea, S., Getting, S. J., Zingarelli, B., Flower, R. J., Salzman, A. L., & Perretti, M. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.7.1041 · Cited by 283
The Role of Poly(ADP-Ribose) Polymerase Activation in the Development of Myocardial and Endothelial Dysfunction in Diabetes
Pacher, P., Liaudet, L., Soriano, F. G., Mabley, J. G., Szabó, É., & Szabó, C. (2002) · Diabetes · doi:10.2337/diabetes.51.2.514 · Cited by 281
Self-citation
Potent Metalloporphyrin Peroxynitrite Decomposition Catalyst Protects Against the Development of Doxorubicin-Induced Cardiac Dysfunction
Pacher, P., Liaudet, L., Bai, P., Mabley, J. G., Kaminski, P. M., Virág, L., Deb, A., Szabó, É., Ungvari, Z. I., Wolin, M. S., et al. (2003) · Circulation · doi:10.1161/01.cir.0000048192.52098.dd · Cited by 279
Poly(ADP-ribose) polymerase 3 (PARP3), a newcomer in cellular response to DNA damage and mitotic progression
Boehler, C., Gauthier, L., Mortusewicz, O., Biard, D. S. F., Saliou, J., Bresson, A., Cianférani, S., Smith, S. H., Schreiber, V., Boussin, F. D., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016574108 · Cited by 277
The role of poly(ADP-ribose) in the DNA damage signaling network
Malanga, M., & Althaus, F. R. (2005) · Biochemistry and Cell Biology · doi:10.1139/o05-038 · Cited by 274
Discovery of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the Treatment of Cancer
Penning, T. D., Zhu, G., Gandhi, V. B., Gong, J., Liu, X., Shi, Y., Klinghofer, V., Johnson, E. F., Donawho, C. K., Frost, D. J., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm801171j · Cited by 273
Development of a Functional Assay for Homologous Recombination Status in Primary Cultures of Epithelial Ovarian Tumor and Correlation with Sensitivity to Poly(ADP-Ribose) Polymerase Inhibitors
Mukhopadhyay, A., Elattar, A., Cerbinskaite, A., Wilkinson, S. J., Drew, Y., Kyle, S., Los, G., Hostomský, Z., Edmondson, R. J., & Curtin, N. J. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2758 · Cited by 271
Self-citation
PARP‐1 gene disruption in mice preferentially protects males from perinatal brain injury
Hagberg, H., Wilson, M. A., Matsushita, H., Zhu, C., Lange, M. S., Gustavsson, M., Poitras, M. F., Dawson, T. M., Dawson, V. L., Northington, F. J., et al. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02547.x · Cited by 269
NAD + as a metabolic link between DNA damage and cell death
Ying, W., Alano, C. C., Garnier, P. E., & Swanson, R. A. (2004) · Journal of Neuroscience Research · doi:10.1002/jnr.20289 · Cited by 269
Inhibition of Poly(ADP-Ribose) Polymerase Enhances Cell Death and Improves Tumor Growth Delay in Irradiated Lung Cancer Models
Albert, J. M., Cao, C., Kim, K. W., Willey, C. D., Geng, L., Xiao, D., Wang, H., Sandler, A. B., Johnson, D. H., Colevas, A. D., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2872 · Cited by 266
Therapeutic Potential of Poly(ADP-ribose) Polymerase Inhibitor AG014699 in Human Cancers With Mutated or Methylated BRCA1 or BRCA2
Drew, Y., Mulligan, E. A., Vong, W., Thomas, H. D., Kahn, S., Kyle, S., Mukhopadhyay, A., Los, G., Hostomský, Z., Plummer, E. R., et al. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq509 · Cited by 265
Self-citation
Protection against peroxynitrite-induced fibroblast injury and arthritis development by inhibition of poly(ADP-ribose) synthase
Szabó, C., Virág, L., Cuzzocrea, S., Scott, G. S., Hake, P. W., O’Connor, M., Zingarelli, B., Salzman, A. L., & Kun, E. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.3867 · Cited by 262
Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas
Kummar, S., Chen, A., Ji, J., Zhang, Y., Reid, J. M., Ames, M., Jia, L., Weil, M., Speranza, G., Murgo, A. J., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1227 · Cited by 259
ARCON: a novel biology-based approach in radiotherapy
Kaanders, J. H., Bussink, J., & van der Kogel, A. J. (2002) · The Lancet Oncology · doi:10.1016/s1470-2045(02)00929-4 · Cited by 257
Role of Poly-ADP Ribosyltransferase Activation in the Vascular Contractile and Energetic Failure Elicited by Exogenous and Endogenous Nitric Oxide and Peroxynitrite
Szabó, C., Zingarelli, B., & Salzman, A. L. (1996) · Circulation Research · doi:10.1161/01.res.78.6.1051 · Cited by 247
Poly(ADP-Ribose) Synthetase Activation Mediates Mitochondrial Injury During Oxidant-Induced Cell Death
Virág, L., Salzman, A. L., & Szabó, C. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.7.3753 · Cited by 246
Structure of the catalytic fragment of poly(AD-ribose) polymerase from chicken.
Ruf, A., Murcia, J. M., de MURCIA, G., & Schulz, G. E. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.15.7481 · Cited by 243
Inhibitors of Poly(Adenosine Diphosphate-Ribose) Synthesis: Effect on Other Metabolic Processes
Milam, K. M., & Cleaver, J. E. (1984) · Science · doi:10.1126/science.6420886 · Cited by 241
Protective effects of PJ34, a novel, potent inhibitor of poly(ADP-ribose) polymerase (PARP) in in vitro and in vivo models of stroke
Abdelkarim, G. E., Gertz, K. R., Harms, C., Katchanov, J., Dirnagl, U., Szabó, C., & Endres, M. (2001) · International Journal of Molecular Medicine · doi:10.3892/ijmm.7.3.255 · Cited by 241
Poly(ADP-Ribose) Polymerase Is Involved in the Development of Diabetic Retinopathy via Regulation of Nuclear Factor-κB
Zheng, L., Szabó, C., & Kern, T. S. (2004) · Diabetes · doi:10.2337/diabetes.53.11.2960 · Cited by 238
Nitrosative stress and pharmacological modulation of heart failure
Pacher, P., Schulz, R., Liaudet, L., & Szabó, C. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.04.003 · Cited by 237
Role of Poly(ADP-Ribose) Polymerase Activation in Diabetic Neuropathy
Obrosova, I. G., Li, F., Abatan, O. I., Forsell, M. A., Komjáti, K., Pacher, P., Szabó, C., & Stevens, M. J. (2004) · Diabetes · doi:10.2337/diabetes.53.3.711 · Cited by 236
Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea.
Liu, L., Markowitz, S. D., & Gerson, S. L. (1996) · PubMed · Cited by 235
Protective effect of melatonin in carrageenan‐induced models of local inflammation: Relationship to its inhibitory effect on nitric oxide production and its peroxynitrite scavenging activity
Cuzzocrea, S., Zingarelli, B., Gilad, E., Hake, P. W., Salzman, A. L., & Szabó, C. (1997) · Journal of Pineal Research · doi:10.1111/j.1600-079x.1997.tb00342.x · Cited by 234
PTEN Loss Compromises Homologous Recombination Repair in Astrocytes: Implications for Glioblastoma Therapy with Temozolomide or Poly(ADP-Ribose) Polymerase Inhibitors
Mcellin, B. M., Camacho, C. V., Mukherjee, B., Hahm, B., Tomimatsu, N., Bachoo, R. M., & Burma, S. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4295 · Cited by 234
Daunorubicin and doxorubicin, anthracycline antibiotics, a physicochemical and biological review
Aubel‐Sadron, G., & Londos‐Gagliardi, D. (1984) · Biochimie · doi:10.1016/0300-9084(84)90018-x · Cited by 233
Reactive oxygen species mediate a cellular ‘memory’ of high glucose stress signalling
Ihnat, M. A., Thorpe, J. E., Kamat, C. D., Szabó, C., Green, D. E., Warnke, L. A., Lacza, Z., Cselenyák, A., Ross, K., Shakir, S. F., et al. (2007) · Diabetologia · doi:10.1007/s00125-007-0684-2 · Cited by 227
Replication-Dependent Radiosensitization of Human Glioma Cells by Inhibition of Poly(ADP-Ribose) Polymerase: Mechanisms and Therapeutic Potential
Dungey, F. A., Löser, D. A., & Chalmers, A. J. (2008) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2008.07.031 · Cited by 227
Protection against myocardial ischemia and reperfusion injury by 3-aminobenzamide, an inhibitor of poly (ADP-ribose) synthetase
Zingarelli, B. (1997) · Cardiovascular Research · doi:10.1016/s0008-6363(97)00137-5 · Cited by 226
Signaling Mechanism of Poly(ADP-Ribose) Polymerase-1 (PARP-1) in Inflammatory Diseases
Ba, X., & Garg, N. J. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2010.12.004 · Cited by 223
Antiinflammatory Effects of Mercaptoethylguanidine, a Combined Inhibitor of Nitric Oxide Synthase and Peroxynitrite Scavenger, in Carrageenan-induced Models of Inflammation
Cuzzocrea, S., Zingarelli, B., Hake, P. W., Salzman, A. L., & Szabó, C. (1998) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(97)00280-3 · Cited by 220
Identification of Genetic Variants in Base Excision Repair Pathway and Their Associations with Risk of Esophageal Squamous Cell Carcinoma
Hao, B., Wang, H., Zhou, K., Li, Y., Chen, X., Zhou, G., Zhu, Y., Miao, X., Tan, W., Wei, Q., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0372 · Cited by 218
Iduna protects the brain from glutamate excitotoxicity and stroke by interfering with poly(ADP-ribose) polymer-induced cell death
Andrabi, S. A., Kang, H. C., Haince, J.-F., Lee, Y.-I., Zhang, J., Chi, Z., West, A. B., Koehler, R. C., Poirier, G. G., Dawson, T. M., et al. (2011) · Nature Medicine · doi:10.1038/nm.2387 · Cited by 216
NMDA But Not Non-NMDA Excitotoxicity is Mediated by Poly(ADP-Ribose) Polymerase
Mandir, A. S., Poitras, M. F., Berliner, A. R., Herring, W. J., Guastella, D. B., Feldman, A. B., Poirier, G. G., Wang, Z., Dawson, T. M., & Dawson, V. L. (2000) · Journal of Neuroscience · doi:10.1523/jneurosci.20-21-08005.2000 · Cited by 213
Attenuation of the induction of nitric oxide synthase by endogenous glucocorticoids accounts for endotoxin tolerance in vivo.
Szabó, C., Thiemermann, C., Wu, C., Perretti, M., & Vane, J. R. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.1.271 · Cited by 213
Failure of Iniparib to Inhibit Poly(ADP-Ribose) Polymerase In Vitro
Patel, A. G., Lorenzo, S. B. D., Flatten, K. S., Poirier, G. G., & Kaufmann, S. H. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2890 · Cited by 213
Peroxynitrite‐induced thymocyte apoptosis: the role of caspases and poly (ADP‐ribose) synthetase (PARS) activation
Virág, L., SCOTT, G. S., Cuzzocrea, S., Marmer, D. J., Salzman, A. L., & Szabó, C. (1998) · Immunology · doi:10.1046/j.1365-2567.1998.00534.x · Cited by 209
Inhibitor and NAD+ Binding to Poly(ADP-ribose) Polymerase As Derived from Crystal Structures and Homology Modeling,
Ruf, A., de MURCIA, G., & Schulz, G. E. (1998) · Biochemistry · doi:10.1021/bi972383s · Cited by 207
Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines
Delaney, C. A., Wang, L. Z., Kyle, S., White, A. W., Calvert, A. H., Curtin, N. J., Durkacz, B. W., Hostomský, Z., & Newell, D. R. (2000) · PubMed · doi:10.25405/ncl.34597155 · Cited by 205
Self-citation
Neuroprotection by tetracyclines
Domercq, M., & Matute, C. (2004) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.10.001 · Cited by 205
Inhibition of PARP-1 by Olaparib (AZD2281) Increases the Radiosensitivity of a Lung Tumor Xenograft
Senra, J. M., Telfer, B. A., Cherry, K. E., McCrudden, C. M., Hirst, D. G., O’Connor, M. J., Wedge, S. R., & Stratford, I. J. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0278 · Cited by 205
Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma.
Tentori, L., Leonetti, C., Scarsella, M., d’Amati, G., Vergati, M., Portarena, I., Xu, W., Kalish, V. J., Zupi, G., Zhang, J., et al. (2003) · PubMed · Cited by 204
Apoptotic morphology of dentate gyrus granule cells following experimental cortical impact injury in rats: possible role in spatial memory deficits
Colicos, M. A., & Dash, P. K. (1996) · Brain Research · doi:10.1016/s0006-8993(96)00824-4 · Cited by 202
Activation of Poly(ADP-Ribose) Polymerase-1 Is a Central Mechanism of Lipopolysaccharide-Induced Acute Lung Inflammation
Liaudet, L., Pacher, P., Mabley, J. G., Virág, L., Soriano, F. G., Haskó, G., & Szabó, C. (2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.165.3.2106050 · Cited by 201
Toll-like receptor 2 and poly(ADP-ribose) polymerase 1 promote central nervous system neuroinflammation in progressive EAE
Farez, M., Quintana, F. J., Gandhi, R., Izquierdo, G., Lucas, M., & Weiner, H. L. (2009) · Nature Immunology · doi:10.1038/ni.1775 · Cited by 199
Temozolomide in malignant gliomas: current use and future targets
Villano, J. L., Seery, T. E., & Bressler, L. R. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-1050-5 · Cited by 198
Association of XRCC1 and tyrosyl DNA phosphodiesterase (Tdp1) for the repair of topoisomerase I-mediated DNA lesions
Plo, I. (2003) · DNA repair · doi:10.1016/s1568-7864(03)00116-2 · Cited by 198
Rapid Reversal of the Diabetic Endothelial Dysfunction by Pharmacological Inhibition of Poly(ADP-Ribose) Polymerase
Soriano, F. G., Pacher, P., Mabley, J. G., Liaudet, L., & Szabó, C. (2001) · Circulation Research · doi:10.1161/hh2001.097797 · Cited by 190
Protection against hemorrhagic shock in mice genetically deficient in poly(ADP-ribose)polymerase
Liaudet, L., Soriano, F. G., Szabó, É., Virág, L., Mabley, J. G., Salzman, A. L., & Szabó, C. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.170226797 · Cited by 190
PARP inhibitors: New partners in the therapy of cancer and inflammatory diseases
Peralta-Leal, A., Rodríguez-Vargas, J. M., Aguilar‐Quesada, R., Rodríguez, M. I., Linares, J. L., de Almodóvar, M. R., & Oliver, F. J. (2009) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2009.04.008 · Cited by 189
Activation of Poly(ADP-Ribose) Polymerase Contributes to Development of Doxorubicin-Induced Heart Failure
Pacher, P., Liaudet, L., Bai, P., Virág, L., Mabley, J. G., Haskó, G., & Szabó, C. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.300.3.862 · Cited by 188
Backup pathways of NHEJ in cells of higher eukaryotes: Cell cycle dependence
Iliakis, G. E. (2009) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2009.06.024 · Cited by 186
Nitric Oxide Toxicity in Islet Cells Involves Poly(ADP-Ribose) Polymerase Activation and Concomitant NAD+ Depletion
Radons, J., Heller, B., Bürkle, A., Hartmann, B., Rodriguez, M.-L., Kröncke, K. D., Burkart, V., & Kolb, H. (1994) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1994.1368 · Cited by 184
Novel phenanthridinone inhibitors of poly(adenosine 5′-diphosphate-ribose) synthetase: Potent cytoprotective and antishock agents*
Jagtap, P. G., Soriano, F. G., Virág, L., Liaudet, L., Mabley, J. G., Szabó, É., Haskó, G., Marton, A., Lorigados, C. B., Gallyas, F., et al. (2002) · Critical Care Medicine · doi:10.1097/00003246-200205000-00019 · Cited by 184
Role of Poly(ADP-Ribose) Polymerase-1 Activation in the Pathogenesis of Diabetic Complications: Endothelial Dysfunction, as a Common Underlying Theme
Pacher, P., & Szabó, C. (2005) · Antioxidants and Redox Signaling · doi:10.1089/ars.2005.7.1568 · Cited by 183
A Novel Methionine-Based Signaling Mechanism Regulating the Expression of Thymidylate Synthase
Chu, E. (2003) · Cancer Biology & Therapy · doi:10.4161/cbt.2.4.460 · Cited by 178
Aldose Reductase Inhibition Counteracts Oxidative-Nitrosative Stress and Poly(ADP-Ribose) Polymerase Activation in Tissue Sites for Diabetes Complications
Obrosova, I. G., Pacher, P., Szabó, C., Zsengellér, Z. K., Hirooka, H., Stevens, M. J., & Yorek, M. A. (2005) · Diabetes · doi:10.2337/diabetes.54.1.234 · Cited by 177
Regulation of microglial expression of integrins by poly(ADP-ribose) polymerase-1
Ullrich, O., Diestel, A., Eyüpoglu, I. Y., & Nitsch, R. (2001) · Nature Cell Biology · doi:10.1038/ncb1201-1035 · Cited by 175
Part I: Pathogenetic Role of Peroxynitrite in the Development of Diabetes and Diabetic Vascular Complications: Studies With FP15, A Novel Potent Peroxynitrite Decomposition Catalyst
Szabó, C., Mabley, J. G., Moeller, S. M., Shimanovich, R., Pacher, P., Virág, L., Soriano, F. G., van Duzer, J. H., Williams, W., Salzman, A. L., et al. (2002) · Molecular Medicine · doi:10.1007/bf03402167 · Cited by 175
Potential role of poly(adenosine 5′-diphosphate-ribose) polymerase activation in the pathogenesis of myocardial contractile dysfunction associated with human septic shock
Soriano, F. G., Nogueira, A. C., Caldini, E. T. E. G., Lins, M., Teixeira, A. C. D., Cappi, S. B., Lotufo, P. A., Bernik, M. M. S., Zsengellér, Z. K., Chen, M., et al. (2006) · Critical Care Medicine · doi:10.1097/01.ccm.0000206470.47721.8d · Cited by 174
In vitro and In vivo Radiosensitization of Glioblastoma Cells by the Poly (ADP-Ribose) Polymerase Inhibitor E7016
Russo, A. L., Kwon, H., Burgan, W. E., Carter, D., Beam, K., Xu, W., Zhang, J., Slusher, B. S., Chakravarti, A., Tofilon, P. J., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2079 · Cited by 172
Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair–deficient malignant glioma xenograft
Cheng, C.-M., Johnson, S. P., Keir, S. T., Quinn, J. A., Ali‐Osman, F., Szabó, C., Li, H., Salzman, A. L., Dolan, M. E., Modrich, P. L., et al. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0128 · Cited by 171
Resistance to Acute Septic Peritonitis in Poly(ADP-ribose) Polymerase-1-Deficient Mice
Soriano, F. G., Liaudet, L., Szab�, �., Vir??g, L., Mabley, J. G., Pacher, P., & Szabó, C. (2002) · Shock · doi:10.1097/00024382-200204000-00008 · Cited by 171
Poly(ADP-Ribose) Polymerase Is Activated in Subjects at Risk of Developing Type 2 Diabetes and Is Associated With Impaired Vascular Reactivity
Szabó, C., Zanchi, A., Komjáti, K., Pacher, P., Królewski, A. S., Quist, W. C., LoGerfo, F. W., Horton, E. S., & Veves, A. (2002) · Circulation · doi:10.1161/01.cir.0000038365.78031.9c · Cited by 171
Polymorphisms in DNA Base Excision Repair Genes ADPRT and XRCC1 and Risk of Lung Cancer
Zhang, X., Miao, X., Liang, G., Hao, B., Wang, Y., Tan, W., Li, Y., Guo, Y., He, F., Wei, Q., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.722.65.3 · Cited by 170
Role of Glutamic Acid 988 of Human Poly-ADP-ribose Polymerase in Polymer Formation
Marsischky, G., Wilson, B. A., & Collier, R. J. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.7.3247 · Cited by 169
Role of nitrosative stress in the pathogenesis of diabetic vascular dysfunction
Szabo, C. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2008.00086.x · Cited by 165
Beneficial effects of 3‐aminobenzamide, an inhibitor of poly (ADP‐ribose) synthetase in a rat model of splanchnic artery occlusion and reperfusion
Cuzzocrea, S., Zingarelli, B., Costantino, G., Szabó, A., Salzman, A. L., Caputi, A. P., & Szabó, C. (1997) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0701234 · Cited by 165
A Phase I Combination Study of Olaparib with Cisplatin and Gemcitabine in Adults with Solid Tumors
Rajan, A., Carter, C. A., Kelly, R. J., Gutierrez, M. E., Kummar, S., Szabo, E. M., Yancey, M. A., Ji, J. J., Mannargudi, B. M., Woo, S., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2425 · Cited by 164
Novel Poly(ADP-ribose) Polymerase-1 Inhibitor, AG14361, Restores Sensitivity to Temozolomide in Mismatch Repair-Deficient Cells
Curtin, N. J., Wang, L.-Z., Yiakouvaki, A., Kyle, S., Arris, C. A., Canan-Koch, S., Webber, S. E., Durkacz, B. W., Calvert, H., Hostomský, Z., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1144-3 · Cited by 164
Self-citation
The ADPRT V762A Genetic Variant Contributes to Prostate Cancer Susceptibility and Deficient Enzyme Function
Lockett, K. L., Hall, M. C., Xu, J., Zheng, S. L., Berwick, M., Chuang, S.-C., Clark, P. E., Cramer, S. D., Lohman, K., & Hu, J. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0338 · Cited by 162
Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study
Samol, J., Ranson, M., Scott, E. N., Macpherson, E., Carmichael, J., Thomas, A., & Cassidy, J. (2011) · Investigational New Drugs · doi:10.1007/s10637-011-9682-9 · Cited by 161
Poly(ADP-Ribose) Polymerase Inhibition Reduces Reperfusion Injury After Heart Transplantation
Szabo, G. B., Bährle, S., Stumpf, N., Sonnenberg, K., Szabó, É., Pacher, P., Csont, T., Schulz, R., Dengler, T. J., Liaudet, L., et al. (2002) · Circulation Research · doi:10.1161/hh0102.102657 · Cited by 161
Myocardial Postischemic Injury Is Reduced by PolyADPribose Polymerase-1 Gene Disruption
Pieper, A. A., Walles, T., Wei, G., Clements, E. E., Verma, A. M., Snyder, S. H., & Zweier, J. L. (2000) · Molecular Medicine · doi:10.1007/bf03401936 · Cited by 156
Clinical perspectives of PARP inhibitors
Graziani, G., & Szabó, C. (2005) · Pharmacological Research · doi:10.1016/j.phrs.2005.02.013 · Cited by 156
Role for nitrosative stress in diabetic neuropathy: evidence from studies with a peroxynitrite decomposition catalyst
Obrosova, I. G., Mabley, J. G., Zsengellér, Z. K., Charniauskaya, T., Abatan, O. I., Groves, J. T., & Szabó, C. (2004) · The FASEB Journal · doi:10.1096/fj.04-1913fje · Cited by 156
Reduction of Cognitive and Motor Deficits after Traumatic Brain Injury in Mice Deficient in Poly(ADP-Ribose) Polymerase
Whalen, M. J., Clark, R. S. B., Dixon, C. E., Robichaud, P., Marion, D. W., Vagni, V., Graham, S. H., Virág, L., Haskó, G., Stachlewitz, R. F., et al. (1999) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-199908000-00002 · Cited by 156
Activation of Microglial Poly(ADP-Ribose)-Polymerase-1 by Cholesterol Breakdown Products during Neuroinflammation
Diestel, A., Aktas, O., Hackel, D., Häke, I., Meier, S., Raine, C. S., Nitsch, R., Zipp, F., & Ullrich, O. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030975 · Cited by 155
Tricyclic Benzimidazoles as Potent Poly(ADP-ribose) Polymerase-1 Inhibitors
Skalitzky, D. J., Marakovits, J. T., Maegley, K. A., Ekker, A., Yu, X., Hostomský, Z., Webber, S. E., Eastman, B. W., Almassy, R. J., Li, J., et al. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm0255769 · Cited by 152
Self-citation
Microglial activation induced by brain trauma is suppressed by post-injury treatment with a PARP inhibitor
d’Avila, J. C., Lam, T. I., Bingham, D., Shi, J., Won, S. J., Kauppinen, T. M., Massa, S. M., Liu, J., & Swanson, R. A. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-31 · Cited by 151
Ca2+‐dependent generation of mitochondrial reactive oxygen species serves as a signal for poly(ADP‐ribose) polymerase‐1 activation during glutamate excitotoxicity
Duan, Y., Gross, R. A., & Sheu, S. (2007) · The Journal of Physiology · doi:10.1113/jphysiol.2007.145409 · Cited by 148
The role of poly(ADP-ribose) polymerase-1 in CNS disease
Kauppinen, T. M., & Swanson, R. A. (2006) · Neuroscience · doi:10.1016/j.neuroscience.2006.09.034 · Cited by 146
Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro
Bowman, K. J., Newell, D. R., Calvert, H., & Curtin, N. J. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2000.1555 · Cited by 144
Self-citation
Cross-sensitivity of γ-ray-sensitive hamster mutants to cross-linking agents
Caldecott, K. W., & Jeggo, P. A. (1991) · Mutation Research/DNA Repair · doi:10.1016/0921-8777(91)90046-r · Cited by 143
Potentiation of anti-cancer agent cytotoxicity by the potent poly(ADP-ribose) polymerase inhibitors NU1025 and NU1064
Bowman, K. J., White, A. W., Golding, B. T., Griffin, R., & Curtin, N. J. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.670 · Cited by 143
Self-citation
Poly(ADP-ribose)polymerase 1 (PARP-1) and postischemic brain damage
Moroni, F. (2007) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2007.10.005 · Cited by 142
GW274150, a potent and highly selective inhibitor of iNOS, reduces experimental renal ischemia/reperfusion injury
Chatterjee, P. K., Patel, N. S. A., Sivarajah, A., Kvale, E. Ø., Dugo, L., Cuzzocrea, S., Brown, P. A., Stewart, K. N., Mota‐Filipe, H., Britti, D., et al. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00802.x · Cited by 142
ABT-888 Confers Broad In vivo Activity in Combination with Temozolomide in Diverse Tumors
Palma, J. P., Wang, Y., Rodriguez, L. E., Montgomery, D., Ellis, P. A., Bukofzer, G. T., Niquette, A. L., Liu, X., Shi, Y., Lasko, L. M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1245 · Cited by 142
Novel Tricyclic Poly(ADP-ribose) Polymerase-1 Inhibitors with Potent Anticancer Chemopotentiating Activity: Design, Synthesis, and X-ray Cocrystal Structure
Koch, S. S. C., Thoresen, L. H., Tikhe, J. G., Maegley, K. A., Almassy, R. J., Li, J., Yu, X., Zook, S. E., Kumpf, R. A., Zhang, C., et al. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020259n · Cited by 141
Self-citation
Cdk1 Participates in BRCA1-Dependent S Phase Checkpoint Control in Response to DNA Damage
Johnson, N., Cai, D. D., Kennedy, R. D., Pathania, S., Arora, M., Li, Y.-C., D’Andrea, A. D., Parvin, J. D., & Shapiro, G. I. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.06.036 · Cited by 141
Association and Interactions between DNA Repair Gene Polymorphisms and Adult Glioma
Liu, Y., Scheurer, M. E., El‐Zein, R. A., Cao, Y., Do, K.-A., Gilbert, M. R., Aldape, K., Wei, Q., Etzel, C. J., & Bondy, M. L. (2009) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-08-0632 · Cited by 139
Oxidative stress and endothelial dysfunction during sepsis
Huet, O. (2010) · Frontiers in bioscience · doi:10.2741/3835 · Cited by 138
Relationship between the intracellular effects of camptothecin and the inhibition of DNA topoisomerase I in cultured L1210 cells.
Mattern, M. R., Mong, S. M., BARTUS, H. F., Mirabelli, C. K., Crooke, S. T., & Johnson, R. K. (1987) · PubMed · Cited by 138
PTEN Deletion in Prostate Cancer Cells Does Not Associate with Loss of RAD51 Function: Implications for Radiotherapy and Chemotherapy
Fraser, M. E., Zhao, H. W., Luoto, K. R., Lundin, C., Coackley, C. L., Chan, N. H. L., Joshua, A. M., Bismar, T. A., Evans, A. J., Helleday, T., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2189 · Cited by 138
Poly(ADP-Ribose) Polymerase Inhibitors Ameliorate Nephropathy of Type 2 Diabetic Leprdb/dbMice
Szabó, C., Biser, A., Benkő, R., Böttinger, E. P., & Suszták, K. (2006) · Diabetes · doi:10.2337/db06-0147 · Cited by 137
Potentiation of temozolomide-induced cytotoxicity: a comparative study of the biological effects of poly(ADP-ribose) polymerase inhibitors
Boulton, S. J., Pemberton, L., Porteous, J. K., Curtin, N. J., Griffin, R., Golding, B. T., & Durkacz, B. W. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.423 · Cited by 136
Self-citation
A novel poly(ADP-ribose) polymerase inhibitor, ABT-888, radiosensitizes malignant human cell lines under hypoxia
Liu, S. K., Coackley, C. L., Krause, M., Jalali, F., Chan, N. H. L., & Bristow, R. G. (2008) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2008.04.005 · Cited by 136
The Novel Poly(ADP-Ribose) Polymerase Inhibitor, AG14361, Sensitizes Cells to Topoisomerase I Poisons by Increasing the Persistence of DNA Strand Breaks
Smith, L. M., Willmore, E., Austin, C. A., & Curtin, N. J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1224 · Cited by 135
Self-citation
From DNA damage and stress signalling to cell death : poly-ADP-ribosylation reactions
de MURCIA, G., & Shall, S. (2000) · Medical Entomology and Zoology · Cited by 134
Anti-inflammatory effects of a novel, potent inhibitor of poly (ADP-ribose) polymerase
Mabley, J. G., Jagtap, P. G., Perretti, M., Getting, S. J., Salzman, A. L., Virág, L., Szabó, É., Soriano, F. G., Liaudet, L., Abdelkarim, G. E., et al. (2001) · Inflammation Research · doi:10.1007/pl00000234 · Cited by 134
Neuronal death in brain infarcts in man
Love, S., Barber, R., & Wilcock, G. K. (2000) · Neuropathology and Applied Neurobiology · doi:10.1046/j.1365-2990.2000.00218.x · Cited by 132
Rapid ‘glycaemic swings’ induce nitrosative stress, activate poly(ADP-ribose) polymerase and impair endothelial function in a rat model of diabetes mellitus
Horvath, E. M., Benkő, R., Kiss, L., Murányi, M., Pék, T., Fekete, K., Bárány, T., Somlai, Á., Csordás, A., & Szabó, C. (2009) · Diabetologia · doi:10.1007/s00125-009-1304-0 · Cited by 132
Poly(ADP-ribose) polymerase-1 (PARP-1) and its therapeutic implications
Sodhi, R. K., Singh, N., & Jaggi, A. S. (2010) · Vascular Pharmacology · doi:10.1016/j.vph.2010.06.003 · Cited by 131
Role of Nitric Oxide in Vascular Permeability after Combined Burns and Smoke Inhalation Injury
Soejima, K., Traber, L. D., Schmalstieg, F. C., Hawkins, H. K., Jodoin, J. M., Szabó, C., Szabó, É., VARIG, L., Salzman, A. L., & Traber, D. L. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.163.3.9912052 · Cited by 131
The inhibition of carbohydrate metabolism in ascites-tumour cells by ethyleneimines
Roitt, I. M. (1956) · Biochemical Journal · doi:10.1042/bj0630300 · Cited by 130

Research works printed but not linked: 3

Du, 2007, Local administration of the poly (ADP-ribose) polymerase inhibitor INO-1001 prevents NAD+ depletion and improves water maze performance after traumatic brain injury in mice, J. Neurotrauma, 24, 1399, 10.1089/neu.2007.0305 · DOI
Komjáti, 2005, Poly(ADP-ribose) polymerase inhibitors as therapeutic agents for stroke and brain trauma. Current Drug Targets, CNS Neurol. Disord., 4, 179
Miknyoczki, 2003, Chemopotentiation of temozlomide, irinotecan and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor, Mol. Cancer Ther., 2, 371

Sorted by citations

Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018.
Galluzzi, L., Vitale, I., Aaronson, S. A., Abrams, J. M., Adam, D., Agostinis, P., Alnemri, E. S., Altucci, L., Amelio, I., Andrews, D. W., et al. (2018) · Cell Death & Differentiation · doi:10.1038/s41418-017-0012-4 · Cited by 6,680
Regulated necrosis: the expanding network of non-apoptotic cell death pathways
Berghe, T. V., Linkermann, A., Jouan-Lanhouet, S., Walczak, H., & Vandenabeele, P. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3737 · Cited by 1,735
NAD+ Metabolism and the Control of Energy Homeostasis: A Balancing Act between Mitochondria and the Nucleus
Cantó, C., Menzies, K. J., & Auwerx, J. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.05.023 · Cited by 1,648
Kynurenine pathway of tryptophan metabolism: regulatory and functional aspects
Badawy, A. A.-B. (2017) · International Journal of Tryptophan Research · doi:10.1177/1178646917691938 · Cited by 1,158
Essential versus accessory aspects of cell death: recommendations of the NCCD 2015
Galluzzi, L., Bravo-San Pedro, J. M., Vitale, I., Aaronson, S. A., Abrams, J. M., Adam, D., Alnemri, E. S., Altucci, L., Andrews, D., Annicchiarico-Petruzzelli, M., et al. (2015) · Cell Death & Differentiation · doi:10.1038/cdd.2014.137 · Cited by 1,002

See all 391

Authors: Curtin, N. J., & Szabo, C.
Affiliations: Newcastle University (GB)
Corresponding author: Curtin, Nicola J.
ORCID: Curtin, Nicola J.
Venue: Molecular Aspects of Medicine
Publisher: Elsevier BV
Published: 2013-12
Volume: 34
Issue: 6
Pages: 1217-1256
ISSN: 0098-2997 (ISSN-L)
DOI: 10.1016/j.mam.2013.01.006
PMC: PMC3657315
OpenAlex: W2017171454
Cited by: 369
References: 559
Citations by year: 2026: 9 · 2025: 17 · 2024: 12 · 2023: 22 · 2022: 25 · 2021: 25 · 2020: 37 · 2019: 31 · 2018: 26 · 2017: 32 · 2016: 38 · 2015: 50 · 2014: 24 · 2013: 21
FWCI: 4.93
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: Molecular Aspects of Medicine (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Newcastle University ePrints (Newcastle Univesity)
Funders: National Institutes of Health
Topics: Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Keywords: PARP inhibitors, poly(ADP-ribose) polymerase, synthetic lethality, homologous recombination deficiency, BRCA mutations, breast cancer, ovarian cancer, temozolomide combination therapy, topoisomerase inhibitors, ionizing radiation, oxidative stress, nitrative stress, necrosis, inflammation, stroke, neurotrauma, shock, acute myocardial infarction, clinical translation
MeSH terms: Poly(ADP-ribose) Polymerase Inhibitors, Animals, Antineoplastic Agents, Cardiovascular Diseases, Clinical Trials as Topic, Enzyme Inhibitors, Humans, Neoplasms, Poly(ADP-ribose) Polymerases, Radiation-Sensitizing Agents, Stroke, Translational Research, Biomedical, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Therapeutic applications of PARP inhibitors: Anticancer therapy and beyond

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks